NERV

Minerva Neurosciences Inc

NERV, USA

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone for the treatment of negative symptoms in patients with schizophrenia. The company also has exclusive rights to develop and commercialize MIN-301, a soluble recombinant form of the Neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.

https://www.minervaneurosciences.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
NERV
stock
NERV

Aug Final Week: Why GSG stock could break out in 2025 moha.gov.vn

Read more →
NERV
stock
NERV

NervGen Pharma (OTCQB: NGENF) Proposes C$2.44 vs US$1.75 Warrant Exercise Price Stock Titan

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

HOLD

Target Price:

$4

Analyst Picks

Strong Buy

0

Buy

0

Hold

1

Sell

0

Strong Sell

0

Sentiment:

Neutral

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very Low

-0.85

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

7.94 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-9.77 %

Low ≤ 2%

High ≥ 10%

Investors

* Institutions hold a combined 75.93% of the total shares of Minerva Neurosciences Inc

1.

Federated Hermes Inc

(19.3221%)

since

2025/06/30

2.

Federated Hermes Kaufmann R

(12.9837%)

since

2025/06/30

3.

Federated Hermes Kaufmann Small Cap A

(10.9689%)

since

2025/06/30

4.

Federated Hermes Kaufmann Growth

(10.3669%)

since

2025/06/30

6.

Vanguard Group Inc

(3.6043%)

since

2025/06/30

7.

Vanguard Total Stock Mkt Idx Inv

(2.4601%)

since

2025/07/31

8.

Renaissance Technologies Corp

(1.5872%)

since

2025/06/30

9.

Geode Capital Management, LLC

(1.0814%)

since

2025/06/30

10.

BlackRock Inc

(1.0391%)

since

2025/06/30

11.

Vanguard Institutional Extnd Mkt Idx Tr

(0.7294%)

since

2025/07/31

12.

Fidelity Total Market Index

(0.4148%)

since

2025/07/31

13.

Federated Hermes Kaufmann II P

(0.3793%)

since

2025/06/30

14.

Fidelity Extended Market Index

(0.3781%)

since

2025/07/31

15.

Apella Capital, LLC

(0.2994%)

since

2025/06/30

16.

Extended Equity Market Fund K

(0.2934%)

since

2025/06/30

17.

State Street Corp

(0.2362%)

since

2025/06/30

18.

LUX IM Global Medtech HX

(0.1868%)

since

2025/08/31

19.

ADAR1 Capital Management LLC

(0.1774%)

since

2025/06/30

20.

Morgan Stanley - Brokerage Accounts

(0.1574%)

since

2025/06/30

21.

Fidelity Series Total Market Index

(0.0963%)

since

2025/07/31

22.

Fidelity Nasdaq Composite Index

(0.0741%)

since

2025/07/31

23.

Spartan Extended Market Index Pool F

(0.0723%)

since

2025/07/31

24.

NT Ext Equity Mkt Idx Fd - L

(0.0719%)

since

2025/06/30

25.

Northern Trust Extended Eq Market Idx

(0.0719%)

since

2025/06/30

26.

NT Ext Equity Mkt Idx Fd - NL

(0.0533%)

since

2025/06/30

27.

Spartan Total Market Index Pool G

(0.0451%)

since

2025/07/31

28.

NT Ext Equity Mkt Idx Fd - DC - NL - T2

(0.0414%)

since

2025/06/30

29.

Extended Equity Market Fund M

(0.0369%)

since

2025/06/30

30.

Tower Research Capital LLC

(0.0317%)

since

2025/06/30

31.

UBS Group AG

(0.0125%)

since

2025/06/30

32.

SBI Securities Co Ltd

(0.0023%)

since

2025/06/30

33.

Northwestern Mutual Wealth Management Co

(0.0014%)

since

2025/06/30

34.

BNP Paribas Arbitrage, SA

(0.0009%)

since

2025/06/30

35.

JONES FINANCIAL COMPANIES LLLP

(0.0008%)

since

2025/06/30

36.

Bank of America Corp

(0.0008%)

since

2025/06/30

37.

Royal Bank of Canada

(0.0007%)

since

2025/06/30

38.

Wells Fargo & Co

(0%)

since

2025/06/30

39.

Northern Trust Corp

(0%)

since

2025/03/31

40.

Citadel Advisors Llc

(0%)

since

2025/06/30

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

-0.11

Latest Release

Date

2025-09-30

EPS Actual

-0.36

EPS Estimate

-0.35

EPS Difference

-0.01

Surprise Percent

-2.8571%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Weak Deep Value(2)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(4.3)
GARP
Not Attractive for GARP(0.5)
Growth
Weak Growth Prospect(0.5)
Momentum
No Momentum(2.5)
Net Net
Not Undervalued (Net-Net)(1)
Quality
Low Quality Business(1)
Value
Overpriced(3)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.